Arrowhead Pharmaceuticals secures NHS funding recommendation for REDEMPLO in familial chylomicronaemia syndrome
REDEMPLO gains NHS backing for genetically confirmed FCS in England and Wales, following strong triglyceride reductions in the PALISADE trial.